Clinical Pharmacokinetics

, Volume 10, Issue 1, pp 1–37 | Cite as

Comparison of Drug Dosing Methods

  • Michael E. Burton
  • Michael R. Vasko
  • D. Craig Brater
  • C. Craig Brater
Review Article


The literature reviewed herein clearly demonstrates the poor correlation between drug dosing and the ability to achieve a specific serum drug concentration and between drug dosing and clinical response, especially for drugs with a narrow therapeutic index. There is, however, a better correlation between serum drug concentration and observed clinical response. Thus, clinicians use serum drug concentrations to more accurately dose drugs.

Numerous dosing methods have been developed in an attempt to improve the relationship between dosing, serum drug concentration, and response. The major hypothesis is that if dosing methods can be developed that will accurately predict serum drug concentration, these methods would be useful in improving clinical care. Several dosing methods have been developed including use of ‘standard’ doses, population-based predictive algorithms and nomograms, pharmacokinetic equations, and Bayesian feedback. Some of these methods are accurate and useful, whereas others are not.

This review evaluates the commonly used dosing methods (some of which utilise serum drug concentration feedback for dosage estimation) for 5 drugs: gentamicin, digoxin, phenytoin, theophylline, and lignocaine (lidocaine). These drugs were selected since they exhibit a representative cross section of pharmacokinetic parameters and since they have narrow therapeutic ranges. An individualised method and a Bayesian method, both using serum drug concentration feedback, appear most accurate and precise in dosing to achieve desired serum drug concentrations and, hence, response. Our bias from personal experience with this method and from published use by others is that the Bayesian method is more flexible in that any number of serum drug concentrations may be used to determine dose, instead of the 3 or more required for the individualised method.

Although use of these methods would appear to be cost-effective in timely provision of health care by reduction of toxicity and hospital stay, only sparse data have been generated to support this conclusion. Thus, further examination of the cost-effectiveness of drug dosing methods is necessary to establish their place in routine patient care.


Digoxin Gentamicin Theophylline Tobramycin Lignocaine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alderman. E.L.; Kerber, R.E. and Harrison, D.C.: Evaluation of lidocaine resistance in man using intermittent large-dose infusion techniques. American Journal of Cardiology 34: 342–349 (1974).PubMedCrossRefGoogle Scholar
  2. Anderson, E.T.; Young, L.S. and Hewitt, W.L.: Simultaneous antibiotic levels in ‘breakthrough’ Gram-negative rod bacteremia. American Journal of Medicine 61: 493–497 (1976).PubMedCrossRefGoogle Scholar
  3. Anderson, G.; Koup, J.R.; Slaughter, R.; Edwards, W.D.; Resmen, B. and Hook, E.: Evaluation of two methods for estimating theophylline clearance prior to achieving steady state. Therapeutic Drug Monitoring 3: 325–332 (1981).PubMedCrossRefGoogle Scholar
  4. Aps, C.; Bell, J.A.; Jenkins, B.S.; Poole-Wilson. P.A. and Reynolds, F.: Logical approach to lignocaine therapy. British Medical Journal 1: 13–15 (1975).CrossRefGoogle Scholar
  5. Aronson, J.K.: Indications for the measurement of plasma digoxin concentrations. Drugs 26: 230–242 (1983).PubMedCrossRefGoogle Scholar
  6. Barza, M.; Brown, R.B.; Shen, D.; Gibaldi, M. and Weinstein, L.: Predictability of blood levels of gentamicin in man. Journal of Infectious Diseases 132: 165–174(1975).PubMedCrossRefGoogle Scholar
  7. Barza, M. and Lauermann, M.: Why monitor serum levels of gentamicin?. Clinical Pharmacokinetics 3: 202–215 (1978).PubMedCrossRefGoogle Scholar
  8. Bassan, M.M.; Weinstein, S.R. and Mandel, W.J.: Use of lidocaine by continuous infusion. American Heart Journal 87: 302–303 (1974).PubMedCrossRefGoogle Scholar
  9. Bauer, L.A. and Blouin, R.A.: Influence of age on amikacin pharmacokinetics in patients without renal disease. Comparison with gentamicin and tobramycin. European Journal of Clinical Pharmacology 24: 639–642 (1983).PubMedCrossRefGoogle Scholar
  10. Bauer, L.A.; Blouin, R.A.; Griffen Jr, W.O.; Record, K.E. and Bell, R.M.: Amikacin pharmacokinetics in morbidly obese patients. American Journal of Hospital Pharmacy 37: 519–522 (1980).PubMedGoogle Scholar
  11. Beach, C.L.; Lernert, L.; Peck, C.; Ludden, T.M.; Farringer, J.A.; Crawford, M.H. and Clementi, W.A.: Evaluation of a two-compartment Bayesian forecasting program for lidocaine during short and long infusions. (Abstract). Clinical Pharmacology and Therapeutics 35: 228 (1984).Google Scholar
  12. Beller, G.A.; Smith, T.W.; Abelmann, W.H.; Haber, E. and Hood, W.B.: Digitalis intoxication. A prospective clinical study with serum level correlations. New England Journal of Medicine 284: 989–997 (1971).PubMedCrossRefGoogle Scholar
  13. Bellet, S.; Roman, L.; Kostis, J.B. and Fleischmann, D.: Intramuscular lidocaine in the therapy of ventricular arrhythmias. American Journal of Cardiology 27: 291–293 (1971).PubMedCrossRefGoogle Scholar
  14. Bennett, P.N.; Aarons, L.J.; Bending, M.R.; Steiner, J.A. and Rowland, M.: Pharmacokinetics of lidocaine and its deethylated metabolite: Dose and time dependency studies in man. Journal of Pharmacokinetics and Biopharmaceutics 10: 265–281 (1982).PubMedCrossRefGoogle Scholar
  15. Bennett, W.M.; Plamp, C.E.; Gilbert, D.N.; Parker, R.A. and Porter, G.A.: The influence of dosage regimen on experimental gentamicin nephrotoxicity: Dissociation of peak serum levels from renal failure. Journal of Infectious Diseases 140: 576–580 (1979).PubMedCrossRefGoogle Scholar
  16. Bernstein, V.; Bernstein, M.; Griffiths, J. and Peretz, D.I.: Lidocaine intramuscularly in acute myocardia! infarction. Journal of the American Medical Association 219: 1027–1031 (1972).PubMedCrossRefGoogle Scholar
  17. Bochner, F.; Hooper, W.D.; Tyrer, J.H. and Eadie, M.J.: Effect of dosage increments on blood phenytoin concentrations. Journal of Neurology, Neurosurgery and Psychiatry 35: 873–876 (1972).CrossRefGoogle Scholar
  18. Bootman, J.L.; Wertheimer, A.I.; Zaske, D. and Rowland, C.: Individualising gentamicin dosage regimens in burn patients with Gram-negative septicemia: A cost-benefit analysis. Journal of Pharmaceutical Sciences 68: 267–272 (1979).PubMedCrossRefGoogle Scholar
  19. Brown, J.E. and Shand, D.G.: Therapeutic drug monitoring of antiarrhythmic agents. Clinical Pharmacokinetics 7: 125–148 (1982).PubMedCrossRefGoogle Scholar
  20. Buchthal, F.; Svensmark, O. and Schiller, P.J.: Clinical and electroencephalographic correlations with serum levels of diphenylhydantoin. Archives of Neurology 2: 624–630 (1960).PubMedCrossRefGoogle Scholar
  21. Buckman, K.; Claiborne, K.; de Guzman, M.; Walberg, C.B. and Haywood, L.J.: Lidocaine efficacy and toxicity assessed by a new rapid method. Clinical Pharmacology and Therapeutics 28: 177–181 (1980).PubMedCrossRefGoogle Scholar
  22. Burton, M.E.; Brater, D.C.; Chen, P.S.; Day, R.B.; Huber, P.J. and Vasko, M.R.: Computer assisted aminoglycoside therapy. (Abstract). Clinical Pharmacology and Therapeutics 35: 230 (1984).Google Scholar
  23. Carliner, N.H.; Gilbert, CA.; Pruitt, A.W. and Goldberg, L.I.: Effects of maintenance digoxin therapy on systolic time intervals and serum digoxin concentrations. Circulation 50: 94–98 (1974).PubMedCrossRefGoogle Scholar
  24. Chamberlain, D.A.; White, R.J.; Howard, M.R. and Smith, T.W.: Plasma digoxin concentrations in patients with atrial fibrillation. British Medical Journal 3: 429–432 (1970).PubMedCrossRefGoogle Scholar
  25. Chan, R.A.; Benner, E.J. and Hoeprich, P.D.: Gentamicin therapy in renal failure: A nomogram for dosage. Annals of Internal Medicine 76: 773–778 (1972).PubMedGoogle Scholar
  26. Chennavasin, P. and Brater, D.C.: Nomograms for drug use in renal disease. Clinical Pharmacokinetics 6: 193–214 (1981).PubMedCrossRefGoogle Scholar
  27. Chiba, K.; Ishizaki, T.; Miura, H. and Minagawa, K.: Michaelis-Menten pharmacokinetics of diphenylhydantoin and application in the pediatric age patient. Journal of Pediatrics 96: 479–484 (1980).PubMedCrossRefGoogle Scholar
  28. Chiou, W.L.; Gadalla, M.A.F. and Peng, G.W.: Method for the rapid estimation of the total body drug clearance and adjustment of dosage regimens in patients during a constant-rate intravenous infusion. Journal of Pharmacokinetics and Biopharmaceutics 6: 135–151 (1978).PubMedCrossRefGoogle Scholar
  29. Chow, M.; Deglin, J.; Harralson, A.; Bartlett, R. and Quintiliani, R.: Prediction of gentamicin serum levels using a one-compartment open linear pharmacokinetic model. American Journal of Hospital Pharmacy 35: 1078–1081 (1978).PubMedGoogle Scholar
  30. Churchill, D.N.; McNamara, J.A.; Bowmer, M.I.; Ahmed, M. and Gault, M.H.: Predictability of serum gentamicin concentrations in renal failure. Cardiovascular Medicine 5: 1307–1310 (1978).Google Scholar
  31. Coca, A.; Blade, J.; Martinez, A.; Segura, F.; Soriano, E. and Ribas-Mundo, M.: Tobramycin nephrotoxicity. A prospective clinical study. Postgraduate Medical Journal 55: 791–796 (1979).PubMedCrossRefGoogle Scholar
  32. Coleman, R.W. and Hedberg, R.L.: Comparison of three methods for estimating theophylline pharmacokinetics. Clinical Pharmacy 2: 148–152 (1983).PubMedGoogle Scholar
  33. Conrad, K.A.; Byers III, J.M.; Finley, P.R. and Burnham, L.: Lidocaine elimination: Effects of metoprolol and of propranolol. Clinical Pharmacology and Therapeutics 33: 133–138 (1983).PubMedCrossRefGoogle Scholar
  34. Cutler, R.E.; Gyselynck, A.; Fleet, W.P. and Forrey, A.W.: Correlation of serum creatinine concentration and gentamicin half-life. Journal of the American Medical Association 219: 1037–1041 (1972).PubMedCrossRefGoogle Scholar
  35. Cutler, R.E. and Orme, B.M.: Correlation of serum creatinine concentration and kanamycin half-life. Therapeutic implications. Journal of the American Medical Association 209: 539–542 (1969).PubMedCrossRefGoogle Scholar
  36. Dahlgren, J.G.; Anderson, E.T. and Hewitt, W.L.: Gentamicin blood levels: A guide to nephrotoxicity. Antimicrobial Agents and Chemotherapy 8: 58–62 (1975).PubMedCrossRefGoogle Scholar
  37. Davidson, C. and Gibson, D.: Clinical significance of positive inotropic action of digoxin in patients with left ventricular disease. British Heart Journal 35: 970–976 (1973).PubMedCrossRefGoogle Scholar
  38. Davison, R.; Parker, M. and Atkinson, A.J.: Excessive serum lidocaine levels during maintenance infusions: Mechanisms and prevention. American Heart Journal 104: 203–208 (1982).PubMedCrossRefGoogle Scholar
  39. Dettli, L.C.: Drug dosage in patients with renal disease. Clinical Pharmacology and Therapeutics 16: 274–280 (1974).PubMedGoogle Scholar
  40. Drayer, D.E.; Lorenzo, B.; Werns, S. and Reidenberg, M.M.: Plasma levels, protein binding, and elimination data of lidocaine and active metabolites in cardiac patients of various ages. Clinical Pharmacology and Therapeutics 34: 14–22 (1983).PubMedCrossRefGoogle Scholar
  41. Duhme, D.W.; Greenblatt, DJ. and Koch-Weser, J.: Reduction of digoxin toxicity associated with measurement of serum levels. A report from the Boston Collaborative Drug Surveillance Program. Annals of Internal Medicine 80: 516–519 (1974).PubMedGoogle Scholar
  42. Dvorchik, B.H. and Vesell, E.S.: Significance of error associated with the use of the one-compartment formula to calculate clearance of thirty-eight drugs. Clinical Pharmacology and Therapeutics 23: 617–623 (1978).PubMedGoogle Scholar
  43. Eaton, M.L.; Green, B.A.; Church, T.R.; McGowan, T. and Niewoehner, D.E.: Efficacy of theophylline in ‘irreversible’ airflow obstruction. Annals of Internal Medicine 92: 758–761 (1980).PubMedGoogle Scholar
  44. Evered, D.C.; Chapman, C. and Hayter, C.J.: Measurement of plasma digoxin concentration by radioimmunoassay. British Medical Journal 3: 427–428 (1970).PubMedCrossRefGoogle Scholar
  45. Fehmers, M.C.O. and Dunning, A.J.: Intramuscularly and orally administered lidocaine in the treatment of ventricular arrhythmias in acute myocardial infarction. American Journal of Cardiology 29: 514–519 (1972).PubMedCrossRefGoogle Scholar
  46. Feig, P.U.; Mitchell, P.P.; Abrutyn, E.; Brock, S.M.; Carney, W.R.; Graeber, C.W.; Horak, E.; Lyons, R.W. and Maher, J.F.: Aminoglycoside nephrotoxicity: A double blind prospective randomized study of gentamicin and tobramycin. Journal of Antimicrobial Chemotherapy 10: 217–226 (1982).PubMedCrossRefGoogle Scholar
  47. Follath, F.; Ganzinger, U. and Schuetz, E.: Reliability of antiar-rhythmic drug plasma concentration monitoring. Clinical Pharmacokinetics 8: 63–82 (1983).PubMedCrossRefGoogle Scholar
  48. Ford, A.R.; Aronson, J.K.; Grahame-Smith, D.G. and Carver, J.G.: Changes in cardiac glycoside receptor sites 86rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients receiving digoxin during the early phases of treatment of cardiac failure in regular rhythm and of atrial fibrillation. British Journal of Clinical Pharmacology 8: 125–134 (1979).PubMedCrossRefGoogle Scholar
  49. French, M.A.; Cerra, F.B.; Plaut, M.E. and Schentag, J.J.: Amikacin and gentamicin accumulation pharmacokinetics and nephrotoxicity in critically ill patients. Antimicrobial Agents and Chemotherapy 19: 147–152 (1981).PubMedCrossRefGoogle Scholar
  50. Gatell, J.M.; San Miquel, J.G.; Zamora, L.; Araujo, V.; Bonet, M.; Bohe, M.; Jiminez De Anta, M.T.; Farre, M.; Elena, M.; Ballesta, A. and Marin, J.L.: Comparison of the nephrotoxicity and auditory toxicity of tobramycin and amikacin. Antimicrobial Agents and Chemotherapy 23: 897–901 (1983).PubMedCrossRefGoogle Scholar
  51. Gerber, N. and Wagner, J.G.: Explanation of dose-dependent decline of diphenylhydantoin plasma levels by fitting to the integrated form of the Michaelis-Menten equation. Research Communications in Chemical Pathology and Pharmacology 3: 455–466 (1972).PubMedGoogle Scholar
  52. Gianelly, R.; Von der Groeben, J.O.; Spivack, A.P. and Harrison, D.C.: Effect of lidocaine on ventricular arrhythmias in patients with coronary heart disease. New England Journal of Medicine 277: 1215–1219 (1967).PubMedCrossRefGoogle Scholar
  53. Gilman, A.G.; Mayer, S.E. and Melmon, K.L.: Pharmacodynamics: Mechanisms of drug action and the relationship between drug concentration and effect; in Gilman et al. (Eds) The Pharmacological Basis of Therapeutics, 6th edition, pp.28–39 (MacMillan, New York 1980).Google Scholar
  54. Goldman, S.; Probst, P.; Selzer, A. and Cohn, K.: Inefficacy of ‘therapeutic’ serum levels of digoxin in controlling the ventricular rate in atrial fibrillation. American Journal of Cardiology 35: 651–655 (1975).PubMedCrossRefGoogle Scholar
  55. Goodman, E.L.; Van Gelder, J.; Holmes, R.; Hull, A.R. and Sanford, J.P.: Prospective comparative study of variable dosage and variable frequency regimens for administration of gentamicin. Antimicrobial Agents and Chemotherapy 8: 434–438 (1975).PubMedCrossRefGoogle Scholar
  56. Grasela, T.H.; Sheiner, L.B.; Rambeck, B.; Boenigk, H.E.; Dunlop, A.; Mullen, P.W.; Wadsworth, J.; Richens, A.; Ishizaki, T.; Chiba, K.; Miura, H.; Minagawa, K.; Blain, P.G.; Mucklow, J.C.; Bacon, C.T. and Rawlins, M.: Steady state pharmacokinetics of phenytoin from routinely collected patient data. Clinical Pharmacokinetics 8: 355–364 (1983).PubMedCrossRefGoogle Scholar
  57. Gyselynck, A.; Forrey, A. and Cutler, R.: Pharmacokinetics of gentamicin: Distribution and plasma and renal clearance. Journal of Infectious Diseases 124 (Suppl.): 570–576 (1971).CrossRefGoogle Scholar
  58. Haerer, A.F. and Grace, J.B.: Studies of anticonvulsant levels in epileptics. Acta Neurologica Scandinavica 45: 18–31 (1969).PubMedCrossRefGoogle Scholar
  59. Halkin, H.; Meffin, P.; Melmon, K.L. and Rowland, M.: Influence of congestive heart failure on blood levels of lidocaine and its active monodeethylated metabolite. Clinical Pharmacology and Therapeutics 17: 669–676 (1975).PubMedGoogle Scholar
  60. Harrison, D.C.: Practical guidelines for the use of lidocaine. Prevention and treatment of cardiac arrhythmias. Journal of the American Medical Association 233: 1202–1204 (1975).PubMedCrossRefGoogle Scholar
  61. Heel, R.C. and Avery, G.S.: Appendix E. Guide to drug dosage in renal failure; in Avery (Ed.) Drug Treatment, 2nd edition, pp. 1290–1303 (ADIS Press, Sydney/New York 1980).Google Scholar
  62. Hendeles, L.; Bighley, L.; Richardson, R.H.; Hepler, C.D. and Carmichael, J.: Frequent toxicity from IV aminophylline infusions in critically ill patients. Drug Intelligence and Clinical Pharmacy 11: 12–18 (1977).Google Scholar
  63. Hendeles, L. and Weinberger, M.: Avoidance of adverse effects during chronic therapy with theophylline. European Journal of Respiratory Disease 61 (Suppl. 109): 103–119 (1980).Google Scholar
  64. Hendeles, L.; Weinberger, M. and Bighley, L.: Disposition of theophylline after a single intravenous infusion of aminophylline. American Review of Respiratory Disease 118: 97–103 (1978).PubMedGoogle Scholar
  65. Hewitt, W.L.: Gentamicin: Toxicity in perspective. Postgraduate Medical Journal 50 (Suppl. 7): 55–59 (1974).PubMedGoogle Scholar
  66. Hoeschen, R.J. and Cuddy, T.E.: Dose-response relation between therapeutic levels of serum digoxin and systolic time intervals. American Journal of Cardiology 35: 469–472 (1975).PubMedCrossRefGoogle Scholar
  67. Hull, J.H. and Sarubbi, F.A.: Gentamicin serum concentrations: Pharmacokinetic predictions. Annals of Internal Medicine 85: 183–189 (1976).PubMedGoogle Scholar
  68. Hyneck, M.L.; Johnson, M.H.; Wagner, J.G. and Williams, G.W.: Comparison of methods for estimating digoxin dosing regimens. American Journal of Hospital Pharmacy 38: 69–73 (1981).PubMedGoogle Scholar
  69. Iisalo, E.: Clinical pharmacokinetics of digoxin. Clinical Pharmacokinetics 2: 1–16 (1977).PubMedCrossRefGoogle Scholar
  70. Ingelfinger, J.A. and Goldman, P.: The serum digitalis concentration — does it diagnose digitalis toxicity?. New England Journal of Medicine 294: 867–870 (1976).PubMedCrossRefGoogle Scholar
  71. Jelliffe, R.W.: Computer-controlled administration of cardiovascular drugs. Progress in Cardiovascular Diseases 26: 1–14 (1983).PubMedCrossRefGoogle Scholar
  72. Jelliffe, R.W. and Brooker, G.: A nomogram for digoxin therapy American Journal of Medicine 57: 63–68 (1974).Google Scholar
  73. Jelliffe, R.W.; Buell, J. and Kalaba, R.: Reduction of digitalis toxicity by computer-assisted glycoside dosage regimens. Annals of Internal Medicine 77: 891–906 (1972).PubMedGoogle Scholar
  74. Jelliffe, R.W.; Schumitzky, A.; D’Argenio, D.Z. and Katz, D.: Improved M.A.P. Bayesian time-shared computer programs for adaptive control of aminoglycoside therapy. (Abstract). Clinical Pharmacology and Therapeutics 33: 255 (1983a).Google Scholar
  75. Jelliffe, R.W.; Schumitzky, A.; D’Argenio, D.Z.; Katz, D. and Nicholson, W.F.: An improved M.A.P. Bayesian computer program for adaptive control of lidocaine therapy. (Abstract). Clinical Pharmacology and Therapeutics 33: 255 (1983b).Google Scholar
  76. Jenne, J.W.; Wyze, E.; Rood, F.S. and MacDonald, F.M.: Pharmacokinetics of theophylline: Application to adjustment of the clinical dose of aminophylline. Clinical Pharmacology and Therapeutics 13: 349–360 (1972).PubMedGoogle Scholar
  77. Jewitt, D.E.; Kishon, Y. and Thomas, M.: Lignocaine in the management of arrhythmias after acute myocardial infarction. Lancet 1: 266–270 (1968).CrossRefGoogle Scholar
  78. Jones, W.N.; Perrier, D.; Trinca, C.E.; Hager, W.D. and Conrad, K.: Evaluation of various methods of digoxin dosing. Journal of Clinical Pharmacology 22: 543–550 (1982).PubMedGoogle Scholar
  79. Jusko, W.J.; Koup, J.R.; Vance, J.W.; Schentag, J.J. and Kuritzky, P.: Intravenous theophylline therapy: Nomogram guidelines. Annals of Internal Medicine 86: 400–404 (1977).PubMedGoogle Scholar
  80. Jusko, W.J.; Gardner, M.J.; Mangione, A.; Schentag, J.J.; Koup, J.R. and Vance, J.W.: Factors affecting theophylline clearances: Age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol. Journal of Pharmaceutical Sciences 68: 1358–1366 (1979).PubMedCrossRefGoogle Scholar
  81. Kaye, D.; Levison, M.E. and Labovitz, E.D.: The unpredictability of serum concentrations of gentamicin: Pharmacokinetics of gentamicin in patients with normal and abnormal renal function. Journal of Infectious Diseases 130: 150–154 (1974).PubMedCrossRefGoogle Scholar
  82. Keys, T.F.; Kurtz, S.B.; Jones, J.D. and Muller, S.M.: Renal toxicity during therapy with gentamicin or tobramycin. Mayo Clinic Proceedings 56: 556–559 (1981).PubMedGoogle Scholar
  83. Klastersky, J.; Daneau, D.; Swings, G. and Weerts, D.: Antibacterial activity in serum and urine as a therapeutic guide in bacterial infections. Journal of Infectious Diseases 129: 187–193 (1974).PubMedCrossRefGoogle Scholar
  84. Knapp, A.B.; Maguire, W.; Keren, G.; Karmen, A.; Levitt, B.; Miura, D.S. and Somberg, J.C.: The cimetidine-lidocaine interaction. Annals of Internal Medicine 98: 174–177 (1983).PubMedGoogle Scholar
  85. Koch-Weser, J.: Serum drug concentrations as therapeutic guides. New England Journal of Medicine 287: 227–231 (1972).PubMedCrossRefGoogle Scholar
  86. Koch-Weser, J.: The serum level approach to individualization of drug dosage. European Journal of Clinical Pharmacology 9: 1–8 (1975).PubMedCrossRefGoogle Scholar
  87. Koch-Weser, J.: Serum procainamide levels as therapeutic guides. Clinical Pharmacokinetics 2: 389–402 (1977).PubMedCrossRefGoogle Scholar
  88. Koch-Weser, J.; Duhme, D.W. and Greenblatt, D.J.: Influence of serum digoxin concentration measurements on frequency of digitoxicity. Clinical Pharmacology and Therapeutics 16: 284–287 (1974).PubMedGoogle Scholar
  89. Kordash, T.R.; Van Dellen, R.G. and McCall, J.T.: Theophylline concentrations in asthmatic patients after administration of aminophylline. Journal of the American Medical Association 238: 139–141 (1977).PubMedCrossRefGoogle Scholar
  90. Koup, J.R.; Greenblatt, D.J.; Jusko, W.J.; Smith, T.W. and Koch-Weser, J.: Pharmacokinetics of digoxin in normal subjects after intravenous bolus and infusion doses. Journal of Pharmacokinetics and Biopharmaceutics 3: 181–192 (1975a).PubMedCrossRefGoogle Scholar
  91. Koup, J.R.; Jusko, W.J.; Elwood, C.M. and Kohli, R.K.: Digoxin pharmacokinetics: Role of renal failure in dosage regimen design. Clinical Pharmacology and Therapeutics 18: 9–21 (1975b).PubMedGoogle Scholar
  92. Koup, J.R.; Sack, C.M.; Smith, A.L. and Gibaldi, M.: Hypothesis for the individualisation of drug dosage. Clinical Pharmacokinetics 4: 460–469 (1979).PubMedCrossRefGoogle Scholar
  93. Koup, J.R.; Schentag, J.J.; Vance, J.W.; Kuritzky, P.M.; Pyszczynski, D.R. and Jusko, W.J.: System for clinical pharmacokinetic monitoring of theophylline therapy. American Journal of Hospital Pharmacy 33: 949–956 (1976).PubMedGoogle Scholar
  94. Kumin, G.D.: Clinical nephrotoxicity of tobramycin and gentamicin. A prospective study. Journal of the American Medical Association 244: 1808–1810 (1980).PubMedCrossRefGoogle Scholar
  95. Kutt, H. and McDowell, F.: Management of epilepsy with diphenylhydantoin sodium: Dosage regulation for problem patients. Journal of the American Medical Association 203: 167–170 (1968).CrossRefGoogle Scholar
  96. Kutt, H.; Winters, W.; Kokenge, R. and McDowell, F.: Diphenylhydantoin metabolism, blood levels, and toxicity. Archives of Neurology 11: 642–648 (1964).PubMedCrossRefGoogle Scholar
  97. Lee, T.H. and Smith, T.W.: Serum digoxin concentration and diagnosis of digitalis toxicity: Current concepts. Clinical Pharmacokinetics 8: 279–285 (1983).PubMedCrossRefGoogle Scholar
  98. Lehmann, C.R. and Leonard, R.G.: Effect of theophylline pharmacokinetic monitoring service on cost and quality of care. American Journal of Hospital Pharmacy 39: 1656–1662 (1982).PubMedGoogle Scholar
  99. LeLorier, J.; Grenon, D.; Latour, Y.; Caille, G.; Dumont, G.; Brosseau, A. and Solignac, A.: Pharmacokinetics of lidocaine after prolonged intravenous infusions in uncomplicated myocardial infarction. Annals of Internal Medicine 87: 700–702 (1977).PubMedGoogle Scholar
  100. Lenert, L.; Peck, C.; Vozeh, S. and Follath, F.: Lidocaine forecaster: A two-compartment Bayesian patient pharmacokinetic computer program. (Abstract). Clinical Pharmacology and Therapeutics 31: 243 (1982).Google Scholar
  101. Lerner, A.M.; Reyes, M.P.; Cone, L.A.; Blair, D.C.; Jansen, W.; Wright, G.E. and Lorber, R.R.: Randomised, controlled trial of the comparative efficacy, auditory toxicity, and nephrotoxicity of tobramycin and netilmicin. Lancet 1: 1123–1126 (1983).PubMedCrossRefGoogle Scholar
  102. Lesar, T.S.; Rotschafer, J.C.; Strand, L.M.; Solem, L.D. and Zaske, D.E.: Gentamicin dosing errors with four commonly used nomograms. Journal of the American Medical Association 248: 1190–1193 (1982).PubMedCrossRefGoogle Scholar
  103. Levy, G. and Koysooko, R.: Pharmacokinetic analysis of the effect of theophylline on pulmonary function in asthmatic children. Journal of Pediatrics 86: 789–793 (1975).PubMedCrossRefGoogle Scholar
  104. Levy, R.A.; Charuzi, Y. and Mandel, W.J.: Lignocaine: A new technique for intravenous administration. British Heart Journal 39: 1026–1028 (1977).PubMedCrossRefGoogle Scholar
  105. Lie, K.I.; Liem, K.L.; Louridtz, W.J.; Janse, M.J.; Willebrands, A.F. and Durrer, D.: Efficacy of lidocaine in preventing primary ventricular fibrillation within 1 hour after a 300mg intramuscular injection — a double-blind randomized study of 300 hospitalized patients with acute myocardial infarction. American Journal of Cardiology 42: 486–488 (1978).PubMedCrossRefGoogle Scholar
  106. Lie, K.I.; Wellens, H.J.; Van Capelle, F.J. and Durrer, D.: Lidocaine in the prevention of primary ventricular fibrillation. New England Journal of Medicine 291: 1324–1326 (1974).PubMedCrossRefGoogle Scholar
  107. Loirat, P.; Rohan, J.; Baillet, A.; Beaufils, F.; David, R. and Chapman, A.: Increased glomerular filtration rate in patients with major burns and its effect on the pharmacokinetics of tobramycin. New England Journal of Medicine 299: 915–919 (1978).PubMedCrossRefGoogle Scholar
  108. Ludden, T.M.; Allen, J.P.; Valutsky, W.A.; Vicuna, A.V.; Nappi, J.M.; Hoffman, S.F.; Wallace, J.E.; Lalka, D. and McNay, J.L.: Individualization of phenytoin dosage regimens. Clinical Pharmacology and Therapeutics 21: 287–293 (1977).PubMedGoogle Scholar
  109. Ludden, T.M.; Beal, S.L.; Peck, C.C.; Yuen, G. and Clementi, W.A.: Bayesian forecasting with nonsteady-state phenytoin data. (Abstract). Clinical Pharmacology and Therapeutics 35: 257 (1984).Google Scholar
  110. Ludden, T.M.; Hawkins, D.W.; Allen, J.P. and Hoffman, S.F.: Optimum phenytoin-dosage regimens. Lancet 1: 307–308 (1976).PubMedCrossRefGoogle Scholar
  111. Lund, L.: Anticonvulsant effect of diphenylhydantoin relative to plasma levels. A prospective three year study in ambulant patients with generalized epileptic seizures. Archives of Neurology 31: 289–294 (1974).PubMedCrossRefGoogle Scholar
  112. Lund, L. and Alvan, G.: Phenytoin dosage nomogram. Lancet 2: 1305–1306 (1975).PubMedCrossRefGoogle Scholar
  113. Martin, E.; Tozer, T.N.; Sheiner, L.B. and Riegelman, S.: The clinical pharmacokinetics of phenytoin. Journal of Pharmacokinetics and Biopharmaceutics 5: 579–597 (1977).PubMedCrossRefGoogle Scholar
  114. Mawer, G.E.; Ahmad, R.; Dobbs, S.M.; McGough, J.G.; Lucas, S.B. and Tooth, J.A.: Prescribing aids for gentamicin. British Journal of Clinical Pharmacology1: 45–50 (1974b).PubMedCrossRefGoogle Scholar
  115. Mawer, G.E.; Mullen, P.W.; Rodgers, M.; Robins, A.J. and Lucas, S.B.: Phenytoin dose adjustment in epileptic patients. British Journal of Clinical Pharmacology 1: 163–168 (1974a).PubMedCrossRefGoogle Scholar
  116. McGory, R.W. and Matzke, G.R.: Evaluation of a single-point method for predicting theophylline dosage. Clinical Pharmacy 1: 441–446 (1982).PubMedGoogle Scholar
  117. McHenry, M.C.; Gavan, T.L.; Gifford, R.W.; Geurkink, N.A.; Van Ommen, R.A.; Town, M.A. and Wagner, J.G.: Gentamicin dosages for renal insufficiency. Adjustments based on endogenous creatinine clearance and serum creatinine concentration. Annals of Internal Medicine 74: 192–197 (1971).PubMedGoogle Scholar
  118. Miller, R.R.: Hospital admissions due to adverse drug reactions. Archives of Internal Medicine 134: 219–223 (1974).PubMedCrossRefGoogle Scholar
  119. Mitenko, P.A. and Ogilvie, R.I.: Rational intravenous doses of theophylline. New England Journal of Medicine 289: 600–603 (1973).PubMedCrossRefGoogle Scholar
  120. Moore, R.D.; Smith, C.R. and Lietman, P.S.: The association of aminoglycoside plasma levels with mortality in patients with Gram-negative bacteremia. Journal of infectious Diseases 149: 443–448 (1984a).PubMedCrossRefGoogle Scholar
  121. Moore, R.D.; Smith, C.R.; Lipsky, J.J.; Mellits, E.D. and Lietman, P.S.: Risk factors for nephrotoxicity in patients treated with aminoglycosides. Annals of Internal Medicine 100: 352–357 (1984b).PubMedGoogle Scholar
  122. Mullen, P.W.: Optimal phenytoin therapy: A new technique for individualizing dosage. Clinical Pharmacology and Therapeutics 23: 228–232 (1978).PubMedGoogle Scholar
  123. Mungall, D.; Bancroft, W. and Marshall, J.: Computer-assisted oral and intravenous theophylline therapy. Computers and Biomedical Research 15: 18–28 (1982).PubMedCrossRefGoogle Scholar
  124. Mungall, D.; Marshall, J.; Penn, D.; Robinson, A.; Scott, J.; Williams, R. and Hurst, D.: Individualizing theophylline therapy: The impact of clinical pharmacokinetics on patient outcomes. Therapeutic Drug Monitoring 5: 95–101 (1983).PubMedCrossRefGoogle Scholar
  125. Narang, P.K.; Crouthamel, W.G.; Carliner, N.H. and Fisher, M.L.: Lidocaine and its active metabolites. Clinical Pharmacology and Therapeutics 24: 654–662 (1978).PubMedGoogle Scholar
  126. Noone, P.; Parsons, T.M.C.; Pattirson, J.R.; Slack, R.C.B.; Garfield-Davies, D. and Hughes, K.: Experience in monitoring gentamicin therapy during treatment of serious Gram-negative sepsis. British Medical Journal 1: 477–481 (1974).PubMedCrossRefGoogle Scholar
  127. Ochs, H.R.; Carstens, G. and Greenblatt, D.J.: Reduction in lidocaine clearance during continuous infusion and by coadministration of propranolol. New England Journal of Medicine 303: 373–377 (1980).PubMedCrossRefGoogle Scholar
  128. Okada, R.D.; Hager, W.D.; Graves, P.E.; Mayersohn, M.; Perrier, D.G. and Marcus, F.I.: Relationship between plasma concentration and dose of digoxin in patients with and without renal impairment. Circulation 58: 1196–1203 (1978).PubMedCrossRefGoogle Scholar
  129. Pancorbo, S.; Davies, S. and Raymond, J.L.: Use of a pharmacokinetic method for establishing doses of aminophylline to treat acute bronchospasm. American Journal of Hospital Pharmacy 38: 851–856 (1981).PubMedGoogle Scholar
  130. Peck, C.C.; Brown, W.D.; Sheiner, L.B. and Schuster, B.G.: A microcomputer drug (theophylline) dosing program which assists and teaches physicians. Proceedings of the Fourth Symposium on Computer Applications in Medical Care: 989-994 (1980).Google Scholar
  131. Peck, C.C.; Sheiner, L.B.; Martin, C.M.; Combs, D.T. and Melmon, K.L.: Computer-assisted digoxin therapy. New England Journal of Medicine 289: 441–446 (1973).PubMedCrossRefGoogle Scholar
  132. Perlin, E.; Peck, C.C. and Nichols, A.I.: An aminoglycoside dosing program using a Bayesian algorithm. Proceedings of the Fifth Annual Symposium on Computer Applications in Medical Care: 610-613 (1981).Google Scholar
  133. Phillips, P.J.; Pain, R.W. and Duncan, B.M.L.: Serum-phenytoin levels. Lancet 2: 926 (1975).PubMedCrossRefGoogle Scholar
  134. Piafsky, K.M. and Ogilvie, R.I.: Dosage of theophylline in bronchial asthma. New England Journal of Medicine 292: 1218–1222 (1975).PubMedCrossRefGoogle Scholar
  135. Platt, D.R.; Matthews, S.J.; Sevka, M.J.; Comer, J.B.; Quintiliani, R.; Cunha, B.A.; Nightingale, C.H. and Chow, M.S.S.: Comparison of four methods of predicting serum gentamicin concentrations in adult patients with impaired renal function. Clinical Pharmacy 1: 361–365 (1982).PubMedGoogle Scholar
  136. Plaut, M.E.; Schentag, J.J. and Jusko, W.J.: Aminoglycoside nephrotoxicity. Comparative assessment in critically ill patients. Journal of Medicine 10: 257–266 (1979).PubMedGoogle Scholar
  137. Powell, J.R.; Vozeh, S.; Hopewell, P.; Costello, J.; Sheiner, L.B. and Riegelman, S.: Theophylline disposition in acutely ill hospitalized patients. The effect of smoking, heart failure, severe airway obstruction, and pneumonia. American Review of Respiratory Disease 118: 229–238 (1978).PubMedGoogle Scholar
  138. Powell, S.H.; Thompson, W.L.; Luthe, M.A.; Stern, R.C.; Grossniklaus, D.A.; Bloxham, D.D.; Groden, D.L.; Jacobs, M.R.; DisCenna, A.O.; Cash, H.A. and Kjinger, J.D.: Once daily vs. continuous aminoglycoside dosing: Efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin. Journal of Infectious Diseases 147: 918–932 (1983).PubMedCrossRefGoogle Scholar
  139. Rambeck, B.; Boenigk, H.E.; Dunlop, A.; Mullen, P.W.; Wadsworth, J. and Richens, A.: Predicting phenytoin dose — a revised nomogram. Therapeutic Drug Monitoring 1: 325–333 (1979).PubMedCrossRefGoogle Scholar
  140. Redfors, A.: Plasma digoxin concentration — its relation to digoxin dosage and clinical effect in patients with atrial fibrillation. British Heart Journal 34: 383–391 (1972).PubMedCrossRefGoogle Scholar
  141. Reigelman, S.; Loo, J.C.K. and Rowland, M.: Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit properties of a single compartment. Journal of Pharmaceutical Sciences 57: 117–123 (1968a).CrossRefGoogle Scholar
  142. Reigelman, S.; Loo, J.C.K. and Rowland, M.: Concept of a volume of distribution and possible errors in evaluation of this parameter. Journal of Pharmaceutical Sciences 57: 128–133 (1968b).CrossRefGoogle Scholar
  143. Reymann, M.T.; Bradac, J.A.; Cobbs, CG. and Dismukes, W.E.: Correlation of aminoglycoside dosages with serum concentrations during therapy of serious Gram-negative bacillary disease. Antimicrobial Agents and Chemotherapy 16: 353–361 (1979).PubMedCrossRefGoogle Scholar
  144. Rich, D.S.; Mahoney, C.D.; Jeffrey, L.P. and Pezzullo, J.C.: Evaluation of a computerized digoxin pharmacokinetic consultation service. Hospital Pharmacy 16: 23–27 (1981).PubMedGoogle Scholar
  145. Richens, A. and Dunlop, A.: Serum-phenytoin levels in management of epilepsy. Lancet 2: 247–248 (1975a).PubMedCrossRefGoogle Scholar
  146. Richens, A. and Dunlop, A.: Phenytoin dosage nomogram. Lancet 2: 1305–1306 (1975b).Google Scholar
  147. Richens, A. and Warrington, S.: When should plasma drug levels be monitored?. Drugs 17: 488–500 (1979).PubMedCrossRefGoogle Scholar
  148. Riddell, J.G.; McAllister, C.B.; Wilkinson, G.R.; Wood, A.J.J. and Roden, D.M.: A new method for constant plasma drug concentrations: Application to lidocaine. Annals of Internal Medicine 100: 25–28 (1984).PubMedGoogle Scholar
  149. Riff, L.J. and Jackson, G.G.: Pharmacology of gentamicin in man. Journal of Infectious Diseases 124 (Suppl.): S98–S105 (1971).PubMedCrossRefGoogle Scholar
  150. Rodensky, P.L.; Wasserman, F. and Gables, C.: Observations on digitalis intoxication. Archives of Internal Medicine 108: 171–188 (1961).PubMedCrossRefGoogle Scholar
  151. Routledge, P.A.; Shand, D.G.; Barchowsky, A.; Wagner, G. and Stargel, W.W.: Relationship between alpha-1-acid glycoprotein and lidocaine disposition in myocardial infarction. Clinical Pharmacology and Therapeutics 30: 154–157 (1981).PubMedCrossRefGoogle Scholar
  152. Routledge, P.A.; Stargel, W.W.; Wagner, G.S. and Shand, D.G.: Increased alpha-1-acid glycoprotein and lidocaine disposition in myocardial infarction. Annals of Internal Medicine 93: 701–704 (1980).PubMedGoogle Scholar
  153. Salzer, L.B.; Weinrib, A.B.; Marina, R.J. and Lima, J.J.: A comparison of methods of lidocaine administration in patients. Clinical Pharmacology and Therapeutics 29: 617–624 (1981).PubMedCrossRefGoogle Scholar
  154. Sarubbi, F.A. and Hull, J.H.: Amikacin serum concentrations: Prediction of levels and dosage guidelines. Annals of Internal Medicine 89: 612–618 (1978).PubMedGoogle Scholar
  155. Sawchuk, R.J.; Zaske, D.E.; Cipolle, R.J.; Wargin, W.A. and Strate, R.G.: Kinetic model for gentamicin dosing with the use of individual patient parameters. Clinical Pharmacology and Therapeutics 21: 362–369 (1977).PubMedGoogle Scholar
  156. Sawyer, D.R.; Ludden, T.M. and Crawford, M.H.: Continuous infusion of lidocaine in patients with cardiac arrhythmias — unpredictability of plasma concentrations. Archives of Internal Medicine 141: 43–45 (1981).PubMedCrossRefGoogle Scholar
  157. Schentag, J.J.; Jusko, W.J.; Plaut, M.E.; Cumbo, T.J.; Vance, J.W. and Abrutyn, E.: Tissue persistence of gentamicin in man. Journal of the American Medical Association 238: 327–329 (1977a).PubMedCrossRefGoogle Scholar
  158. Schentag, J.J.; Jusko, W.J.; Vance, J.W.; Cumbo, T.J.; Abrutyn, E.; DeLattre, M. and Gerbracht, L.M.: Gentamicin disposition and tissue accumulation on multiple dosing. Journal of Pharmacokinetics and Biopharmaceutics 5: 559–577 (1977b).PubMedCrossRefGoogle Scholar
  159. Schentag, J.J.; Lasezkay, G.; Cumbo, T.J.; Plaut, M.E. and Jusko, W.J.: Accumulation pharmacokinetics of tobramycin. Antimicrobial Agents and Chemotherapy 13: 649–656 (1978).PubMedCrossRefGoogle Scholar
  160. Schentag, J.J.; Plaut, M.E.; Cerra, F.B.; Wels, P.B.; Walczak, P. and Buckley, R.J.: Aminoglycoside nephrotoxicity in critically ill surgical patients. Journal of Surgical Research 26: 270–279 (1979).CrossRefGoogle Scholar
  161. Schentag, J.J.; Plaut, M.E. and Cerra, F.B.: Comparative nephrotoxicity of gentamicin and tobramycin. Pharmacokinetic and clinical studies in 201 patients. Antimicrobial Agents and Chemotherapy 19: 859–866 (1981).PubMedCrossRefGoogle Scholar
  162. Schumacher, G.E.: Using pharmacokinetics in drug therapy. VI: Comparing methods for dealing with non-linear drugs like phenytoin. American Journal of Hospital Pharmacy 37: 128–132 (1980).PubMedGoogle Scholar
  163. Shapiro, W.; Narahara, K. and Taubert, K.: Relationship of plasma digitoxin and digoxin to cardiac response following intravenous digitalization in man. Circulation 47: 1065–1072 (1970).CrossRefGoogle Scholar
  164. Sheiner, L.B. and Beal, S.L.: Some suggestions for measuring predictive performance. Journal of Pharmacokinetics and Biopharmaceutics 9: 503–512 (1981).PubMedCrossRefGoogle Scholar
  165. Sheiner, L.B. and Beal, S.L.: Bayesian individualization of pharmacokinetics: Simple implementation and comparison with non-Bayesian methods. Journal of Pharmaceutical Sciences 71: 1344–1348 (1982).PubMedCrossRefGoogle Scholar
  166. Sheiner, L.B.; Beal, S.; Rosenberg, B. and Marathe, V.V.: Forecasting individual pharmacokinetics. Clinical Pharmacology and Therapeutics 26: 294–305 (1979).PubMedGoogle Scholar
  167. Sheiner, L.B.; Halkin, H.; Peck, G.; Rosenberg, B. and Melmon, K.L.: Improved computer-assisted digoxin therapy. A method using feedback of measured serum digoxin concentration. Annals of Internal Medicine 82: 619–627 (1975).PubMedGoogle Scholar
  168. Sheiner, L.B.; Rosenberg, B. and Melmon, K.L.: Modelling of individual pharmacokinetics for computer-aided drug dosage. Computers and Biomedical Research 5: 441–459 (1972).CrossRefGoogle Scholar
  169. Singh, J.B. and Kocot, S.L.: A controlled trial of intramuscular lidocaine in the prevention of premature ventricular contractions associated with acute myocardial infarction. American Heart Journal 91: 430–436 (1976).PubMedCrossRefGoogle Scholar
  170. Sketris, I.; Lesar, T.; Zaske, D.E. and Cipolle. R.J.: Effect of obesity on gentamicin pharmacokinetics. Journal of Clinical Pharmacology 21: 288–293 (1981).PubMedGoogle Scholar
  171. Slattery, J.T.; Gibaldi, M. and Koup, J.R.: Pharmacokinetic concepts: Prediction of maintenance dose required to attain a desired drug concentration at steady-state from a single determination of concentration after an initial dose. Clinical Pharmacokinetics 5: 377–385 (1980).PubMedCrossRefGoogle Scholar
  172. Smith, C.R.; Baughman, K.L.; Edwards, C.Q.; Rogers, J.F. and Lietman, P.S.: Controlled comparison of amikacin and gentamicin. New England Journal of Medicine 296: 349–353 (1977).PubMedCrossRefGoogle Scholar
  173. Smith, C.R.; Lipsky, J.J.; Laskin, O.L.; Hellmann, D.B.; Mellits, E.D.; Longstreth, J. and Lietman, P.S.: Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. New England Journal of Medicine 302: 1106–1109 (1980).PubMedCrossRefGoogle Scholar
  174. Smith, T.W.: Digitalis toxicity: Epidemiology and clinical use of serum concentration measurements. American Journal of Medicine 58: 470–476 (1975).PubMedCrossRefGoogle Scholar
  175. Smith, T.W.; Butler, V.P. and Haber, E.: Determination of therapeutic and toxic serum digoxin concentrations by radio-immunoassay. New England Journal of Medicine 281: 1212–1216 (1969).PubMedCrossRefGoogle Scholar
  176. Smith, T.W. and Haber, E.: Digoxin intoxication: The relationship of clinical presentation to serum digoxin concentration. Journal of Clinical Investigation 49: 2377–2386 (1970).PubMedCrossRefGoogle Scholar
  177. Solem, L.D.; Zaske, D. and Strate, R.G.: Ecthyma gangrenosum — survival with individualized antibiotic therapy. Archives of Surgery 114: 580–583 (1979).PubMedCrossRefGoogle Scholar
  178. Stargel, W.W.; Shand, D.G.; Routledge, P.A.; Barchowsky, A. and Wagner, G.S.: Clinical comparison of rapid infusion and multiple injection methods for lidocaine loading. American Heart Journal 102: 872–876 (1981).PubMedCrossRefGoogle Scholar
  179. Stenson, R.E.; Constantino, R.T. and Harrison, D.C.: Interrelationships of hepatic blood flow, cardiac output, and blood levels of lidocaine in man. Circulation 43: 205–211 (1971).PubMedCrossRefGoogle Scholar
  180. Thomson, P.D.; Melmon, K.L.; Richardson, J.A.; Cohn, K.; Steinbrunn, W.; Cudihee, R. and Rowland, M.: Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans. Annals of Internal Medicine 78: 499–508 (1973).PubMedGoogle Scholar
  181. Tozer, T.N.: Nomogram for modification of dosage regimens in patients with chronic renal function impairment. Journal of Pharmacokinetics and Biopharmaceutics 2: 13–28 (1974).CrossRefGoogle Scholar
  182. Upton, R.A.; Thiercelin, J.F.; Guentert, T.W.; Wallace, S.M.; Powell, J.R.; Sansom, L. and Riegelman, S.: Intraindividual variability of theophylline pharmacokinetics: Statistical verification in 39 of 60 healthy young adults. Journal of Pharmacokinetics and Biopharmaceutics 10: 123–133 (1982).PubMedCrossRefGoogle Scholar
  183. US Food and Drug Administration: I.V. dosage guidelines for theophylline products. FDA Drug Bulletin 10: 4–6 (Feb 1980).Google Scholar
  184. Vozeh, S.; Berger, M.; Ritz, R. and Follath, F.: Accurate prediction of lidocaine individual dosage requirements. (Abstract). Clinical Pharmacology and Therapeutics 33: 212 (1983).Google Scholar
  185. Vozeh, S.; Kewitz, G.; Perruchond, A.; Tschan, M.; Kopp, C.; Heitz, M. and Follath, F.: Theophylline serum concentration and therapeutic effect in severe acute bronchial obstruction: The optimal use of intravenously administered aminophylline. American Review of Respiratory Disease 125: 181–184 (1982).PubMedGoogle Scholar
  186. Vozeh, S.; Kewitz, G.; Wenk, M. and Follath, F.: Rapid prediction of steady-state serum theophylline concentration in patients treated with intravenous aminophylline. European Journal of Clinical Pharmacology 18: 473–477 (1980a).PubMedCrossRefGoogle Scholar
  187. Vozeh, S.; Koelz, A.; Martin, E.; Magun, H.; Scollo-Lavizzari, G. and Follath, F.: Predictability of phenytoin serum levels by nomograms and clinicians. European Neurology 19: 345–352 (1980b).PubMedCrossRefGoogle Scholar
  188. Vozeh, S.; Muir, K.T.; Sheiner, L.B. and Follath, F.: Predicting individual phenytoin dosage. Journal of Pharmacokinetics and Biopharmaceutics 9: 131–146 (1981).PubMedCrossRefGoogle Scholar
  189. Wagner, J.G.; Yates, J.D.; Willis III, P.W.; Sakmar, E. and Stoll, R.G.: Correlation of plasma levels of digoxin in cardiac patients with dose and measures of renal function. Clinical Pharmacology and Therapeutics 15: 291–301 (1974).PubMedGoogle Scholar
  190. Wagner, J.G. and co-workers: Pharmacokinetic parameters estimated from intravenous data by uniform methods and some of their uses. Journal of Pharmacokinetics and Biopharmaceutics 5: 161–182 (1977).PubMedCrossRefGoogle Scholar
  191. Weinberger, M.W.; Matthay, R.A.; Ginchansky, E.J.; Chidsey, C.A. and Petty, T.L.: Intravenous aminophylline dosage. Use of serum theophylline measurement for guidance. Journal of the American Medical Association 235: 2110–2113 (1976).PubMedCrossRefGoogle Scholar
  192. Weintraub, M.: Interpretation of the serum digoxin concentration. Clinical Pharmacokinetics 2: 205–219 (1977).PubMedCrossRefGoogle Scholar
  193. Wilkinson, G.R. and Shand, D.C.: A physiological approach to hepatic drug clearance. Clinical Pharmacology and Therapeutics 18: 377–390 (1975).PubMedGoogle Scholar
  194. Winters, R.E.; Litwack, R.D. and Hewitt, W.L.: Relation between dose and levels of gentamicin in blood. Journal of Infectious Diseases 124 (Suppl.): S90–S95 (1971).PubMedCrossRefGoogle Scholar
  195. Wyman, M.G.; Lalka, D.; Hammersmith, L.; Cannom, D.S. and Goldreyer, B.N.: Multiple bolus technique for lidocaine administration during the first hours of an acute myocardial infarction. American Journal of Cardiology 41: 313–317 (1978).PubMedCrossRefGoogle Scholar
  196. Wyman, M.G.; Slaughter, R.L.; Farolino, D.A.; Gore, S.; Cannom, D.S.; Goldreyer, B.N. and Lalka, D.: Multiple bolus technique for lidocaine administration in acute ischemic heart disease. II. Treatment of refractory ventricular arrhythmias and the pharmacokinetic significance of severe left ventricular failure. Journal of the American College of Cardiology 2: 764–769 (1983).PubMedCrossRefGoogle Scholar
  197. Yee, G.C. and Evans, W.E.: Reappraisal of guidelines for pharmacokinetic monitoring of aminoglycosides. Pharmacotherapy 1: 55–75 (1981).PubMedGoogle Scholar
  198. Zaske, D.E.; Bootman, J.L.; Solem, L.B. and Strate, R.G.: Increased burn patient survival with individualized dosages of gentamicin. Surgery 91: 142–149 (1982a).PubMedGoogle Scholar
  199. Zaske, D.E.; Cipolle, R.J.; Rotschafer, J.C.; Solem, L.D.; Mosier, N.R. and Strate, R.G.: Gentamicin pharmacokinetics in 1640 patients: Method for control of serum concentrations. Antimicrobial Agents and Chemotherapy 21: 407–411 (1982b).PubMedCrossRefGoogle Scholar
  200. Zaske, D.E.; Cipolle, R.J. and Strate, R.J.: Gentamicin dosage requirements: Wide interpatient variations in 242 surgery patients with normal renal function. Surgery 87: 164–169 (1980a).PubMedGoogle Scholar
  201. Zaske, D.E.; Cipolle, R.J.; Strate, R.G.; Malo, J.W. and Koszalka Jr, M.F.: Rapid gentamicin elimination in obstetric patients. Obstetrics and Gynecology56: 559–564 (1980b).PubMedGoogle Scholar
  202. Zaske, D.E.; Cipolle, R.J.; Strate, R.G. and Dickes, W.F.: Increased gentamicin dosage requirements: Rapid elimination in 249 gynecology patients. American Journal of Obstetrics and Gynecology 139: 896–900 (1981).PubMedGoogle Scholar
  203. Zaske, D.E.; Irving, P.; Strand, L.M.; Strate, R.G.; Cipolle, R.J. and Rotschafer, J.: Wide interpatient variations in gentamicin dose requirements for geriatric patients. Journal of the American Medical Association 248: 3122–3126 (1982c).PubMedCrossRefGoogle Scholar
  204. Zaske, D.E.; Sawchuk, R.J.; Gerding, D.N. and Strate, R.G.: Increased dosage requirements of gentamicin in burn patients. Journal of Trauma 16: 824–828 (1976).PubMedCrossRefGoogle Scholar
  205. Zener, J.C.; Kerber, R.E.; Spivack, A.P. and Harrison, D.C.: Blood lidocaine levels and kinetics following high-dose intramuscular administration. Circulation 47: 984–988 (1973).PubMedCrossRefGoogle Scholar
  206. Zito, R.A. and Reid, P.R.: Lidocaine kinetics predicted by indocyanine green clearance. New England Journal of Medicine 298: 1160–1163 (1978).PubMedCrossRefGoogle Scholar
  207. Zito, R.A. and Reid, P.R.: Lidocaine kinetics: Relationship between early lidocaine kinetics and indocyanine green clearance. Journal of Clinical Pharmacology 21: 100–105 (1981).PubMedGoogle Scholar
  208. Zito, R.A.; Reid, P.R. and Longstreth, J.A.: Variability of early lidocaine levels in patients. American Heart Journal 94: 292–296 (1977).PubMedCrossRefGoogle Scholar
  209. Zwillich, C.W.; Sutton, F.D.; Neff, T.A.; Cohn, W.M.; Matthay, R.A. and Weinberger, M.M.: Theophylline-induced seizures in adults: Correlation with serum concentrations. Annals of Internal Medicine 82: 784–787 (1975).PubMedGoogle Scholar

Copyright information

© ADIS Press Limited 1985

Authors and Affiliations

  • Michael E. Burton
    • 1
  • Michael R. Vasko
    • 1
  • D. Craig Brater
    • 1
  • C. Craig Brater
    • 1
  1. 1.Pharmacology Section and Department of Pharmacology, Dallas Veterans Administration Medical CenterUniversity of Texas Health Science Center at Dallas; College of Pharmacy, University of Texas at AustinUSA

Personalised recommendations